Allergan BIOCELL Class Action

Wittels McInturff Palikovic has filed a class action lawsuit against Allergan on behalf of a number of women implanted with recalled Allergan Biocell® Textured Breast Implants and Tissue Expanders.

Our class action attorneys have had considerable success in bringing companies to justice that have injured people financially, emotionally, and physically – and we are seeking justice for women affected by Allergan’s unreasonably dangerous products.

If you have been adversely affected by Allergan’s implants and would like to speak with one of our experienced attorneys about this class-action lawsuit and your experience with these recalled products, please contact our office at attorneys@wittelslaw.com or 914-775-8862.

These implants and expanders were the subject of a July 2019 recall by the U.S. Food and Drug Administration (FDA) due to significant concerns that the implants may cause breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), an immune system cancer.

The FDA has identified the following implants as part of this recall:

  • Allergan Natrelle Saline-Filled Breast Implants (previously sold as the McGhan RTV Saline-Filled Mammary Implant) in styles 163, 168, 363 and 468;

  • Allergan Natrelle Silicone-Filled Textured Breast Implants (previously known as Inamed Silicone-Filled Breast Implants) in styles 110, 115, 120, TRL, TRLP, TRM, TRF, TRX, TCL, TCLP, TCM, TCF, TCX, TSL, TSLP, TSM, TSF, and TSX;

  • Natrelle 410 Highly Cohesive Anatomically Shaped Silicone Filled Breast Implants in styles 410FM, 410FF, 410MM, 410 MF, 410 ML, 410 LL, 410 LM, 410 LF, 410 FX, 410 MX, and 410 LX.

The tissue expanders that have been recalled are:

  • Natrelle 133 Plus Tissue Expander;

  • Natrelle133 Tissue Expander with Suture Tabs.

The FDA’s analysis found that the risk of BIA-ALCL was approximately six times the risk of BIA-ALCL with textured implants from other manufacturers. The Agency warned that the continued distribution of Allergan's BIOCELL textured breast implants would likely cause serious, adverse health consequences, including death, from BIA-ALCL.

FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D. stated in a press release: “Although the overall incidence of BIA-ALCL appears to be relatively low, once the evidence indicated that a specific manufacturer’s product appeared to be directly linked to significant patient harm, including death, the FDA took action to alert the firm to new evidence indicating a recall is warranted to protect women’s health”.

In December 2019, the Judicial Panel on Multi-District Litigation (JPML) ordered that all Allergan cases pending in Federal Courts throughout the country be transferred to the U.S. District Court for the District of New Jersey and assigned to the Honorable Brian R. Martinotti.  Accordingly you should be aware that irrespective of where you live, if you decide to bring suit, your case is likely to proceed in New Jersey federal court.

The Class Action Complaint in Allergan can be found here.